GILEAD SCIENCES, INC.

GILD· Nasdaq· Biological Products, (No Diagnostic Substances)

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
32.1%
ROIC, 5 yr avg
14.5%
Revenue, 5 yr CAGR
+3.6%
We record prices for the companies we cover; GILD is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
1.25B
Revenue
$29.4B
Free cash flow
$9.5B
Owner earnings
$8.6B

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
–
Operating
34.0%
Net
28.9%
Free cash flow
32.1%
Owner earnings
29.1%
Stock pay
3.0%

Returns

ROIC, FY2025
21.8%
ROIC, 5 yr avg
14.5%
ROE, FY2025
37.5%
ROE, 5 yr avg
23.2%

Growth (CAGR)

Revenue, 3 yr
2.6%
Revenue, 5 yr
3.6%
Revenue, 9 yr
-0.4%
Diluted EPS, 3 yr
23.0%
Diluted EPS, 5 yr
132.4%
Diluted EPS, 9 yr
-4.2%
Free cash flow, 3 yr
4.3%
Free cash flow, 5 yr
4.7%
Free cash flow, 9 yr
-5.9%

Financial health · FY2025

Cash and investments
$7.6B
Total debt
$24.9B
Net debt
$17.3B
Debt/Equity
1.1x
Debt/FCF
2.6x

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
47.0%
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
-0.1%

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$29.4B

-0.4% a year over 9 years

FY2016: Revenue $30.4BFY2017: Revenue $26.1BFY2018: Revenue $22.1BFY2019: Revenue $22.4BFY2020: Revenue $24.7BFY2021: Revenue $27.3BFY2022: Revenue $27.3BFY2023: Revenue $27.1BFY2024: Revenue $28.8BFY2025: Revenue $29.4B
FY2016FY2025

Margins

Operating34.0%Net28.9%

FY2025

FY2016: Operating 58.0%, Net 44.4%FY2017: Operating 54.1%, Net 17.7%FY2018: Operating 37.1%, Net 24.7%FY2019: Operating 19.1%, Net 24.0%FY2020: Operating 16.5%, Net 0.5%FY2021: Operating 36.3%, Net 22.8%FY2022: Operating 26.9%, Net 16.8%FY2023: Operating 28.0%, Net 20.9%FY2024: Operating 5.8%, Net 1.7%FY2025: Operating 34.0%, Net 28.9%
FY2016FY2025

Free cash flow and owner earnings

Free cash flow$9.5BOwner earnings$8.6B

Free cash flow -5.9% a year

FY2016: Free cash flow $16.3B, Owner earnings $15.9BFY2017: Free cash flow $11.3B, Owner earnings $10.7BFY2018: Free cash flow $7.5B, Owner earnings $6.6BFY2019: Free cash flow $8.3B, Owner earnings $7.7BFY2020: Free cash flow $7.5B, Owner earnings $6.9BFY2021: Free cash flow $10.8B, Owner earnings $10.2BFY2022: Free cash flow $8.3B, Owner earnings $7.7BFY2023: Free cash flow $7.4B, Owner earnings $6.7BFY2024: Free cash flow $10.3B, Owner earnings $9.5BFY2025: Free cash flow $9.5B, Owner earnings $8.6B
FY2016FY2025

Diluted shares

1.25B

-7.6% over 9 years, net buybacks

FY2016: Diluted shares 1.36BFY2017: Diluted shares 1.32BFY2018: Diluted shares 1.31BFY2019: Diluted shares 1.28BFY2020: Diluted shares 1.26BFY2021: Diluted shares 1.26BFY2022: Diluted shares 1.26BFY2023: Diluted shares 1.26BFY2024: Diluted shares 1.25BFY2025: Diluted shares 1.25B
FY2016FY2025

Return on invested capital

21.8%

FY2025

FY2016: ROIC 41.7%FY2017: ROIC 17.0%FY2018: ROIC 30.8%FY2019: ROIC –FY2020: ROIC 0.5%FY2021: ROIC 18.0%FY2022: ROIC 14.4%FY2023: ROIC 15.3%FY2024: ROIC 3.2%FY2025: ROIC 21.8%
FY2016FY2025

Net debt (below zero)

-$17.3B

$17.3B more debt than cash

FY2016: Net cash -$14.5BFY2017: Net cash -$8.0BFY2018: Net cash $2.8BFY2019: Net cash -$241.0MFY2020: Net cash -$24.0BFY2021: Net cash -$20.2BFY2022: Net cash -$18.8BFY2023: Net cash -$17.7BFY2024: Net cash -$16.7BFY2025: Net cash -$17.3B
FY2016FY2025

Every figure, year by year

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
The business
Revenue$30.4B$26.1B$22.1B$22.4B$24.7B$27.3B$27.3B$27.1B$28.8B$29.4B
Revenue growth-6.9%-14.1%-15.2%1.5%10.0%10.6%-0.1%-0.6%6.0%2.4%
Gross margin––––––––––
Operating margin58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%34.0%
Net income$13.5B$4.6B$5.5B$5.4B$123.0M$6.2B$4.6B$5.7B$480.0M$8.5B
Net margin44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%
Diluted EPS$9.94$3.51$4.17$4.22$0.10$4.93$3.64$4.50$0.38$6.78
Return on invested capital?41.7%17.0%30.8%–0.5%18.0%14.4%15.3%3.2%21.8%
Cash
Operating cash flow$17.0B$11.9B$8.4B$9.1B$8.2B$11.4B$9.1B$8.0B$10.8B$10.0B
Capital expenditure$748.0M$590.0M$924.0M$825.0M$650.0M$579.0M$728.0M$585.0M$523.0M$563.0M
Free cash flow$16.3B$11.3B$7.5B$8.3B$7.5B$10.8B$8.3B$7.4B$10.3B$9.5B
Stock-based compensation$380.0M$638.0M$845.0M$636.0M$643.0M$635.0M$637.0M$766.0M$835.0M$894.0M
Owner earnings?$15.9B$10.7B$6.6B$7.7B$6.9B$10.2B$7.7B$6.7B$9.5B$8.6B
Free cash flow per share$12.00$8.57$5.72$6.51$5.95$8.56$6.61$5.90$8.21$7.53
Capital allocation
Dividends paid$2.5B$2.7B$3.0B$3.2B$3.4B$3.6B$3.7B$3.8B$3.9B$4.0B
Share repurchases$11.0B$954.0M$2.9B$1.7B$1.6B$546.0M$1.4B$1.0B$1.1B$1.9B
Diluted shares1.36B1.32B1.31B1.28B1.26B1.26B1.26B1.26B1.25B1.25B
Share count change?-10.7%-2.9%-0.8%-2.4%-1.1%-0.1%0.0%-0.3%-0.2%0.0%
Balance sheet
Cash and equivalents$8.2B$7.6B$17.9B$11.6B$6.0B$5.3B$5.4B$6.1B$10.0B$7.6B
Short-term investments$3.7B$17.9B$12.1B$12.7B$1.4B$1.2B$973.0M$1.2B$0$68.0M
Total debt$26.3B$33.5B$27.3B$24.6B$31.4B$26.7B$25.2B$25.0B$26.7B$24.9B
Net debt$14.5B$8.0B-$2.8B$241.0M$24.0B$20.2B$18.8B$17.7B$16.7B$17.3B
Shareholders' equity$18.9B$20.4B$21.4B$22.5B$18.2B$21.1B$21.2B$22.8B$19.3B$22.7B

Latest filings

All on EDGAR
2026-10-3010-QQuarterly report
2026-10-298-KEarnings release
2026-08-0610-QQuarterly report
2026-08-048-KEarnings release
2026-05-0710-QQuarterly report
2026-05-078-KEarnings release
2026-03-20DEF 14AProxy statement
2026-02-2410-KAnnual report
2026-02-108-KEarnings release
2025-11-0710-QQuarterly report

More from our coverage

All coverage